A photo of James Mulloy.

Co-Leader, Hematological Malignancy Program

Professor, UC Department of Pediatrics

513-636-1844

513-636-3768

Biography & Affiliation

Academic Affiliation

Professor, UC Department of Pediatrics

Departments

Experimental Hematology and Cancer Biology, Cancer and Blood Diseases

Education

BA: St. Anselm College, Manchester, NH, 1986.

MS: Rutgers University-University of Medicine and Dentistry, New Brunswick, NJ, 1989.

PhD: Rutgers University-University of Medicine and Dentistry, New Brunswick, NJ, 1992.

Publications

Small-Molecule Targeting of Oncogenic FTO Demethylase in Acute Myeloid Leukemia. Huang, Y; Su, R; Sheng, Y; Dong, L; Dong, Z; Xu, H; Ni, T; Zhang, ZS; Zhang, T; Li, C; et al. Cancer Cell. 2019; 35:677-691.e10.

Alternative translation initiation generates the N-terminal truncated form of RUNX1 that retains hematopoietic activity. Goyama, S; Schibler, J; Mulloy, JC. Experimental Hematology. 2019; 72:27-35.

Improved multilineage human hematopoietic reconstitution and function in NSGS mice. Wunderlich, M; Chou, F; Sexton, C; Presicce, P; Chougnet, CA; Aliberti, J; Mulloy, JC. PLoS ONE. 2018; 13:e0209034-e0209034.

Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response. Barve, A; Casson, L; Krem, M; Wunderlich, M; Mulloy, JC; Beverly, LJ. Experimental Hematology. 2018; 67:18-31.

METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m(6)A Modification. Weng, H; Huang, H; Wu, H; Qin, X; Zhao, BS; Dong, L; Shi, H; Skibbe, J; Shen, C; Hu, C; et al. Cell Stem Cell. 2018; 22:191-205.e9.

R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m(6)A/MYC/CEBPA Signaling. Su, R; Dong, L; Li, C; Nachtergaele, S; Wunderlich, M; Qing, Y; Deng, X; Wang, Y; Weng, X; Hu, C; et al. Cell. 2018; 172:90-105.e23.

Cell polarity and division symmetry analyses in transformed blood cells. Mizukawa, B; O’Brien, E; Mulloy, JC; Zheng, Y. Methods in molecular biology (Clifton, N.J.). 2018; 1821:257-266.

Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Jiang, X; Hu, C; Ferchen, K; Nie, J; Cui, X; Chen, C; Cheng, L; Zuo, Z; Seibel, W; He, C; et al. Nature Communications. 2017; 8.

Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells. Eriksson, M; Peña-Martínez, P; Ramakrishnan, R; Chapellier, M; Högberg, C; Glowacki, G; Orsmark-Pietras, C; Velasco-Hernandez, T; Lazarevic, VL J; Juliusson, G; et al. Blood Advances. 2017; 1:2046-2057.

The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation. Mizukawa, B; O'Brien, E; Moreira, DC; Wunderlich, M; Hochstetler, CL; Duan, X; Liu, W; Orr, E; Grimes, HL; Mulloy, JC; et al. Blood. 2017; 130:1336-1346.